Information Provided By: 
Fly News Breaks for August 9, 2019
AMRN
Aug 9, 2019 | 08:19 EDT
Jefferies analyst Michael Yee views today's selloff in shares of Amarin as a buying opportunity. It is reasonable to have a drug this big discussed in public forum, Yee tells investors in a research note. While the FDA panel brings "some new risk," the corresponding stock selloff more than reflecting this, says Yee. He sees a "buying opportunity since approval is very likely." Yee reiterates a Buy rating on Amarin with a $30 price target.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
